Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142): evaluation report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal
01 - Overview prepared by NICE
02 - Assessment Report prepared by Peninsula Technology Assessment Group
03 - Comments on the Assessment Report - Amgen
04 - Comments on the Assessment Report - Target Ovarian
05 - Comments on the Assessment Report - Royal College Pathologists and BSCH
06 - Comments on the Assessment Report - Royal College of Nursing
07 - Comments on the Assessment Report - Janssen
08 - Comments on the Assessment Report - Department of Health
09 - Response to comments on the Assessment Report prepared by Peninsula Technology Assessment Group
10 - Executive summary of technology manufacturer’s submission - Amgen
11 - Executive summary of technology manufacturer’s submission - Sandoz
12 - Consultee submission - Myeloma UK
Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142): evaluation report
15 April 2014 (9.28 Mb 8 sec) |
This page was last updated: 15 April 2014